123 related articles for article (PubMed ID: 18521799)
61. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
62. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer.
Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E
Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478
[TBL] [Abstract][Full Text] [Related]
63. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
64. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
[TBL] [Abstract][Full Text] [Related]
65. Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.
Abe S; Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Watanabe T
J Surg Res; 2016 Oct; 205(2):384-392. PubMed ID: 27664887
[TBL] [Abstract][Full Text] [Related]
66. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
67. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
68. Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
Willsher PC; Beaver J; Blamey RW; Robertson JF
Anticancer Res; 1995; 15(4):1609-11. PubMed ID: 7654057
[TBL] [Abstract][Full Text] [Related]
69. The Role of TPS and TPA in the Diagnostics of Distant Metastases.
Kucera R; Topolcan O; Fiala O; Kinkorova J; Treska V; Zedníková I; Slouka D; Simanek V; Safanda M; Babuska V
Anticancer Res; 2016 Feb; 36(2):773-7. PubMed ID: 26851038
[TBL] [Abstract][Full Text] [Related]
70. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
71. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
72. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
73. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
74. Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Kou T; Kanai M; Yamamoto M; Xue P; Mori Y; Kudo Y; Kurita A; Uza N; Kodama Y; Asada M; Kawaguchi M; Masui T; Mizumoto M; Yazumi S; Matsumoto S; Takaori K; Morita S; Muto M; Uemoto S; Chiba T
Int J Clin Oncol; 2016 Feb; 21(1):118-25. PubMed ID: 26123314
[TBL] [Abstract][Full Text] [Related]
75. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer.
Louhimo J; Carpelan-Holmström M; Alfthan H; Stenman UH; Järvinen HJ; Haglund C
Int J Cancer; 2002 Oct; 101(6):545-8. PubMed ID: 12237895
[TBL] [Abstract][Full Text] [Related]
76. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
77. TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis.
Slesak B; Harlozinska-Szmyrka A; Knast W; Sedlaczek P; Einarsson R; van Dalen A
Int J Biol Markers; 2004; 19(2):115-9. PubMed ID: 15255543
[TBL] [Abstract][Full Text] [Related]
78. Time-frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer.
Sato A; Masui T; Yogo A; Ito T; Hirakawa K; Kanawaku Y; Koike K; Uemoto S
Sci Rep; 2020 Dec; 10(1):21941. PubMed ID: 33318606
[TBL] [Abstract][Full Text] [Related]
79. Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.
Guo Q; Kang M; Zhang B; Chen Y; Dong X; Wu Y
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1627-31. PubMed ID: 20174821
[TBL] [Abstract][Full Text] [Related]
80. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
